bluebird bio Inc Spotlight on bb1111 for Sickle Cell Disease Conference Call Transcript
' -
Good morning, everyone, and thank you for joining today's presentation. My name is Courtney O'Leary, Investor Relations at bluebird bio.
Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995, including financial projections in addition to statements of the company's plans, expectations or intentions regarding development of our clinical programs and commercialization plans following potential regulatory approval. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. A description of these risks is contained in our filings with the SEC, which are available on the Investor Relations section of our website, www.bluebirdbio.com.
While we may elect to update forward-looking statements in the future, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
